Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.51 |
| ▸ | MGLL | Q99685 | 4/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14240811 | 0.95 | MGLL (0.54) | PTGS1PTGS2MGLLFAAHHSD17B10 | |
| SCHEMBL12132672 | 0.94 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHCASP2 | |
| SCHEMBL12642012 | 0.92 | PTGS1 (0.54) | PTGS1PTGS2MGLLFAAHHSD17B10 | |
| SCHEMBL11915911 | 0.90 | PTGS1 (0.46) | PTGS1PTGS2MGLLFAAHMEN1 | |
| SCHEMBL14984835 | 0.90 | PTGS1 (0.49) | PTGS1PTGS2MGLLFAAHHSD17B10 | |
| SCHEMBL19380535 | 0.89 | PTGS1 (0.60) | PTGS1PTGS2MGLLFAAHHSD17B10 | |
| SCHEMBL15728340 | 0.89 | PTGS1 (0.44) | PTGS1PTGS2MGLLFAAHCASP2 | |
| SCHEMBL18995821 | 0.88 | PTGS1 (0.51) | PTGS1PTGS2MGLLFAAHCASP2 | |
| SCHEMBL22967351 | 0.88 | MGLL (0.43) | PTGS1PTGS2MGLLFAAHHSD17B10 | |
| SCHEMBL15613431 | 0.88 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044214-A1 | HEMICYANINE PUSH-PULL DYES BASED ON CHROMENE ELECTRON DONORS | UNIVERSITY OF CONNECTICUT (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230323028-A1 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | SKINOSIVE (FR) | 2023-10-12 | — | — | US | disclosed |
| WO-2023141445-A1 | ANTI-NOTCH2 ANTIBODIES AND CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230174605-A1 | IL-2 SEQUENCES AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-06-08 | — | — | US | disclosed |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
| US-10961313-B2 | Anti-factor D antibody variant conjugates and uses thereof | GENENTECH, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3777898-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10654932-B2 | Anti-factor D antibody variant conjugates and uses thereof | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3250232-B1 | BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF | DYNAVAX TECH CORP (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20200115462-A1 | ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF | GENENTECH INC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20110286956-A1 | NOVEL MULTI-ARM POLYETHYLENE GLYCOL, PREPARATION METHOD AND USES THEREOF | BEIJING JENKEM TECHNOLOGY CO. LTD. (CN) | 2011-11-24 | — | — | US | disclosed |
| US-8012488-B2 | Polyoxyalkylene derivative | NOF CORPORATION (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20110105392-A1 | Pegylated Insulin Lispro Compounds | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2010129864-A2 | METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090215981-A1 | Glp-1 Pegylated Compounds | ELI LILLY AND COMPANY | 2009-08-27 | — | — | US | disclosed |
| US-20090176253-A1 | Antibody conjugates | VENTANA MEDICAL SYSTEMS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090023859-A1 | POLYOXYALKYLENE DERIVATIVE | NOF CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961313-B2 | Anti-factor D antibody variant conjugates and uses thereof | CFD, CFH, F13B | PTGS1 3508/4885PTGS2 4132/4885MGLL 2441/4885 |
| US-20230323028-A1 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | ICAM1, CDH1, VCAM1 | PTGS1 1018/4885PTGS2 1388/4885MGLL 3691/4885 |
| US-20110286956-A1 | NOVEL MULTI-ARM POLYETHYLENE GLYCOL, PREPARATION METHOD AND USES THEREOF | GNE, MRPL21, MRPL38 | PTGS1 2064/4885PTGS2 2056/4885MGLL 53/4885 |
| US-20110105392-A1 | Pegylated Insulin Lispro Compounds | IAPP, IDE, LIPE | PTGS1 307/4885PTGS2 663/4885MGLL 231/4885 |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | PTGS1 2785/4885PTGS2 1725/4885MGLL 2421/4885 |
| US-20090215981-A1 | Glp-1 Pegylated Compounds | GIPR, GLP1R, IAPP | PTGS1 1589/4885PTGS2 2635/4885MGLL 62/4885 |
| US-20200115462-A1 | ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF | CFD, CFH, F13B | PTGS1 3508/4885PTGS2 4132/4885MGLL 2441/4885 |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | TLR3, TLR1, TLR6 | PTGS1 846/4885PTGS2 1001/4885MGLL 2260/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | PTGS1 3341/4885PTGS2 3588/4885MGLL 3095/4885 |
| US-20230174605-A1 | IL-2 SEQUENCES AND USES THEREOF | IL2, IL2RA, IL4I1 | PTGS1 975/4885PTGS2 170/4885MGLL 4502/4885 |
| US-10654932-B2 | Anti-factor D antibody variant conjugates and uses thereof | CFD, CFH, F13B | PTGS1 3508/4885PTGS2 4132/4885MGLL 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.